Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products that use Enzon’s PEGylation technology.

“Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases,” said Jeffrey H. Buchalter, Enzon’s chairman and chief executive officer.